| Biologic Therapy |
0 |
0.92 |
| Antineoplastic Drug |
0 |
0.83 |
| Monoclonal Antibody |
0 |
0.83 |
| Scleroderma |
0 |
0.76 |
| Lung |
0 |
0.43 |
| Lung Fibrosis |
0 |
0.36 |
| Interstitial Lung Disease |
0 |
1 |
| Systemic Sclerosis |
0 |
0.99 |
| Revenue and Practice Management |
0 |
0.11 |
| Idiopathic Pulmonary Fibrosis |
0 |
0.09 |
| Brachial |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Grant |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| White Blood Cell Count |
0 |
0.06 |
| Blood |
0 |
0.04 |
| C-Reactive Protein (CRP) |
0 |
0.04 |
| Corticosteroids |
0 |
0.04 |
| Diarrhea |
0 |
0.04 |
| Mucositis |
0 |
0.04 |
| Myositis |
0 |
0.04 |
| Neutrophils |
0 |
0.04 |
| New York |
0 |
0.04 |
| Prognosis |
0 |
0.04 |
| Salary and Compensation |
0 |
0.04 |
| Surgery |
0 |
0.04 |
| Vasculitis |
0 |
0.04 |